Objective To evaluate the efficacy, toxicity, and operative complications of docetaxel in combination with S-1 for treating patients with advanced gastric cancer. Methods From July 2013 to December 2014, 30 patients with advanced gastric cancer were treated with i.v. docetaxel 75 mg/m~2 on day 1 and oral S-1 60 mg/m~2 bid on days 1–14 every 3 weeks. The efficacy and toxicity were evaluated after two chemotherapy cycles. Results The overall treatment response(complete response [CR] + partial response [PR]) was 76.6%(23/30), CR was 6.7%(2/30), PR was 70.0%(21/30), SD was 23.3%(7/30), and progression disease was 0%(0/30). All patients were treated surgically. Twenty-six patients received radical surgery; of them, 23 received D2 lymph node dissection. The other four patients received exploratory celiotomy. No patients died in the group, and the adverse reactions included neutropenia, diarrhea, nausea, and vomiting. Conclusion Docetaxel/S-1 combination is highly active, safe, and well tolerated in patients with advanced gastric cancer. Further investigations in randomized studies are warranted. Objective To evaluate the efficacy, toxicity, and operative complications of docetaxel in combination with S-1 for treating patients with advanced gastric cancer. Methods From July 2013 to December 2014, 30 patients with advanced gastric cancer were treated with iv docetaxel 75 mg / m ~ 2 on day 1 and oral S-1 60 mg / m ~ 2 bid on days 1-14 every 3 weeks. The efficacy and toxicity were evaluated after two chemotherapy cycles. Results The overall treatment response (complete response [CR] + partial response rate was 76.6% (23/30), CR was 6.7% (2/30), PR was 70.0% (21/30), SD was 23.3% (7/30), and progression disease was 0% All patients were treated surgically. Twenty-six patients received radical surgery; of them, 23 received D2 lymph node dissection. The other four patients received exploratory celiotomy. No patients died in the group, and the adverse reactions included neutropenia, diarrhea, nausea, and vomiting. Conclusion Docetaxel / S-1 combination is highly active, safe, and well tol erated in patients with advanced gastric cancer. Further investigations in randomized studies are warranted.